Lung Cancer
Volume 64, Issue 2 , Pages 155-159 , May 2009

Aberrant methylation of tumour-related genes in thymic epithelial tumours

  • Yukiko Hirose

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Kazuya Kondo

      Affiliations

    • Department of Oncological Medical Services, Institute of Health Biosciences, The University of Tokushima Graduate School, 18-15 Kuramoto-cho 3, Tokushima 770-8509, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 88 633 9031; fax: +81 88 633 9031.
    • ,
  • Hiromitsu Takizawa

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Taeko Nagao

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Yasushi Nakagawa

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Haruhiko Fujino

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Hiroaki Toba

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Koichiro Kenzaki

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Shoji Sakiyama

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan
    • ,
  • Akira Tangoku

      Affiliations

    • Department of Oncological and Regenerative Surgery, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan

Received 22 May 2008 ,Revised 29 July 2008 ,Accepted 30 July 2008.

References 

  1. Rosai J, Levine GD. Tumor of the thymus. Atlas of tumor pathology, 2nd series. fascicle 13. Washington, DC: Armed Forces Institute of Pathology; 1976;
  2. Shimosato Y, Mukai K. Tumors of the mediastinum. Atlas of tumor pathology, 3rd series. fascicle 21. Washington, DC: Armed Forces Institute of Pathology; 1997;
  3. Shimosato Y. Controversies surrounding the subclassification of thymoma. Cancer. 1994;74:542–544
  4. Rosai J. Histological typing of tumours of the thymus. WHO International histological classification of tumours. 2nd ed.. New York: Springer-Verlag; 1999;pp. 5–15
  5. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO classification of tumours. 2nd ed.. Lyon: IARC Press; 2004;pp. 145–97
  6. Nomori H, Horinouchi H, Kaseda S, Ishihara T, Torikata C. Evaluation of malignant grade of thymoma by morphometric analysis. Cancer. 1998;61:982–988
  7. Asamura H, Nakajima T, Mukai K, Noguchi M, Shimosato Y. Degree of malignancy of thymic epithelial tumors in terms of nuclear DNA content and nuclear area. An analysis of 39 cases. Am J Pathol. 1988;133:615–622
  8. Yang WI, Efird JT, Quintanilla-Martinez L, Choi N, Harris NL. Cell kinetic study of thymic epithelial tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies. Hum Pathol. 1996;27:70–76
  9. Pich A, Chiarle R, Chiusa L, Palestro G. Argyrophilic nucleolar organizer region counts predict survival in thymoma. Cancer. 1994;74:1568–1574
  10. Hino N, Kondo K, Miyoshi T, Uyama T, Monden Y. High frequency of p53 protein expression in thymic carcinoma but not in thymoma. Br J Cancer. 1997;76:1361–1366
  11. Sogawa K, Kondo K, Fujino H, Takahashi Y, Miyoshi T, Sakiyama S, et al. Increased expression of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 correlate with poor prognostic variables in thymic epithelial tumors. Cancer. 2003;98:1822–1829
  12. Suzuki M, Chen H, Shigematu H, Ando S, Iida T, Nakajima T, et al. Aberrant methylation in thymic carcinomas, rare in thymomas. Oncol. Rep. 2005;14:1621–1624
  13. Hirabayashi H, Fujii Y, Sakaguchi M, Tanaka H, Yoon H, Komoto Y, et al. p16 INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer. 1997;73:639–644
  14. Zettl A, Ströbel P, Wagner K, Katzenberger T, Ott G, Rosenwald A, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol. 2000;157:257–266
  15. Zhou R, Zettl A, Ströbel P, Wagner K, Müller-Hermelink HK, Zhang SJ, et al. Thymic epithelial tumors can develop along two different pathogenetic pathways. Am J Pathol. 2001;159:1853–1860
  16. Inoue M, Starostik P, Zettl A, Ströbel P, Schwarz S, Scaravilli F, et al. Correlating genetic aberrations with World Health Organization-defined histology and stage across the spectrum of thymomas. Cancer Res. 2003;63:3708–3715
  17. Jass JR. Colorectal cancer: a multipathway disease. Crit Rev Oncog. 2006;12:273–287
  18. Oyama T, Osaki T, Mitsudomi T, Ogawa R, Nakanishi R, Sugio K, et al. p53 alteration, proliferating cell nuclear antigen, and nucleolar organizer regions in thymic epithelial tumors. Int J Mol Med. 1998;1:823–826
  19. Weirich G, Schneider P, Fellbaum C, Brauch H, Narthrath W, Scholz M, et al. p53 alterations in thymic epithelial tumours. Virchows Arch. 1997;431:17–23
  20. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48:2485–2492
  21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821–9826
  22. Zöchbauer-Müller S, FongKM , Virmani AK, Geradts J, Gazdar AF, Minna JD. Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res. 2001;61:249–255
  23. Tsou J, Hagen J, Carpenter C, Laird-Offringa I. DNA methylation analysis: a powerful new tool for lung cancer diagnosis. Oncogene. 2002;21:5450–5461
  24. Belinsky S, Palmisano W, Gilliland F, Crooks L, Divine K, Winters S, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002;62:2370–2377
  25. Kondo K, Yoshizawa K, Tsuyuguchi M, Kimura S, Sumitomo M, Morita J, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg. 2004;77:1183–1188
  26. Detterbeck F. Clinical value of the WHO classification system of thymoma. Ann Thorac Surg. 2006;81:2328–2334
  27. Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990;50:6119–6129
  28. Jacinto F, Esteller M. MGMT hypermethylation: a prognostic foe, a predictive friend. DNA Repair. 2007;6:1155–1160
  29. Brabender J, Usadel H, Metzger R, Schneider P, Park J, Salonga D, et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin Cancer Res. 2003;9:223–227
  30. Komine C, Watanabe T, Katayama Y, Yoshino A, Yokoyama T, Fukushima T. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is an independent predictor of shortened progression free survival in patients with low-grade diffuse astrocytomas. Brain Pathol. 2003;13:176–184
  31. Koga Y, Kitajima Y, Miyoshi A, Sato K, Kitahara K, Soejimaand H, et al. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. Ann Surg Oncol. 2005;12:354–363
  32. Esteller M, Garcia-Foncillas J, Andion E, Goodman S, Hidalgo O, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350–1354
  33. Esteller M, Gaidano G, Goodman S, Zagonel V, Capello D, Botto B, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94:26–32
  34. Loehrer PJ, Kim KM, Aisner SC, Livingston R, Einhorn LH, Johnson D, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol. 1994;12:1164–1168
  35. Loehrer PJ, Jiroutek M, Aisner S, Aisner j , Green M, Thomas LR, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma an intergroup trial. Cancer. 2001;91:2010–2015
  36. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, et al. Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res. 2005;11:6505–6518

PII: S0169-5002(08)00416-9

doi: 10.1016/j.lungcan.2008.07.015

Lung Cancer
Volume 64, Issue 2 , Pages 155-159 , May 2009

Article Tools

* Image Usage & Resolution